Apixaban for preventing stroke and systemic embolism in people with non-valvular atrial
KEYWORDS: apixaban, stroke, warfarin, dabigatran, committee, embolism, people, systemic, systemic embolism, compared, fibrillation, atrial, atrial fibrillation, patients, manufacturer

4.1 The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of apixaban, having considered evidence on the nature of non- valvular atrial fibrillation and the value placed on the benefits of apixaban by people with the condition, those who represent them, and clinical specialists. It also took into account the effective use of NHS resources. 4.2 The Committee heard from clinical specialists and patient experts that the current standard treatment for people with non-valvular atrial fibrillation who need anticoagulation is warfarin or the newer oral anticoagulants rivaroxaban or dabigatran. The clinical specialists explained that the majority of people receiving an anticoagulant currently receive warfarin. In addition, some people who meet criteria for anticoagulation are currently receiving the antiplatelet agent aspirin inappropriately because of clinical reluctance to prescribe warfarin. The Committee heard that warfarin is an effective treatment but that it is associated with a number of problems. The patient experts explained that repeated INR monitoring tests with warfarin can cause pain and scarring and limit a person's choice of leisure or other activities and that warfarin can have a greater impact on a person's quality of life than atrial fibrillation itself. They also highlighted that warfarin
